Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias.
about
Epigenetic approaches in the treatment of myelodysplastic syndromes: clinical utility of azacitidineTreating refractory leukemias in childhood, role of clofarabineChildhood acute myeloid leukaemiaAllo-SCT conditioning for myelodysplastic syndrome and acute myeloid leukemia with clofarabine, cytarabine and ATG.Prolonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory, aggressive non-Hodgkin lymphoma.Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I TrialFinal results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia.Polyadenylation inhibition by the triphosphates of deoxyadenosine analogues.A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndromeAAML0523: a report from the Children's Oncology Group on the efficacy of clofarabine in combination with cytarabine in pediatric patients with recurrent acute myeloid leukemia.Clofarabine in leukemia.Low dose of homoharringtonine and cytarabine combined with granulocyte colony-stimulating factor priming on the outcome of relapsed or refractory acute myeloid leukemia.A randomized study of 2 dose levels of intravenous clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome.The role of clofarabine in acute myeloid leukemia.High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B study 19902.Southwest Oncology Group Study S0530: a phase 2 trial of clofarabine and cytarabine for relapsed or refractory acute lymphocytic leukaemia.Clofarabine: past, present, and future.Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias.Clofarabine: a new treatment option for patients with acute myeloid leukemia.Clofarabine: emerging role in leukemias.Clofarabine for the treatment of adult acute myeloid leukemia.Clofarabine combined with busulfan provides excellent disease control in adult patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation.Clofarabine and high-dose cytosine arabinoside in the treatment of refractory or relapsed acute myeloid leukaemia.A phase I study of fludarabine, cytarabine, and oxaliplatin therapy in patients with relapsed or refractory acute myeloid leukemia.Current Approaches in the Treatment of Relapsed and Refractory Acute Myeloid Leukemia.Report of a phase II study of clofarabine and cytarabine in de novo and relapsed and refractory AML patients and in selected elderly patients at high risk for anthracycline toxicity.Combination chemotherapy with clofarabine, cyclophosphamide, and etoposide in children with refractory or relapsed haematological malignancies.Emerging pharmacotherapies for adult patients with acute lymphoblastic leukemia.Clofarabine salvage therapy in refractory multifocal histiocytic disorders, including Langerhans cell histiocytosis, juvenile xanthogranuloma and Rosai-Dorfman disease.A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias.Phase 1 dose-escalation trial of clofarabine followed by escalating dose of fractionated cyclophosphamide in adults with relapsed or refractory acute leukaemiasValproic acid synergistically enhances the cytotoxicity of clofarabine in pediatric acute myeloid leukemia cells.Phase I/II trial of clofarabine and cytarabine in children with relapsed/refractory acute lymphoblastic leukemia (AAML0523): a report from the Children's Oncology Group.Clofarabine for the treatment of acute lymphoblastic leukemia.Clofarabine in the treatment of acute myeloid leukemia in older adultsClofarabine with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming for relapsed and refractory acute myeloid leukaemiaOral clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome.Pretransplant NPM1 MRD levels predict outcome after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemiaLaromustine (cloretazine).Acute myeloid leukaemia in the elderly: a review.
P2860
Q24608659-72F2B6E9-FAB8-4DA1-AD5D-D926915C9254Q24647279-7D6DECAF-77E6-46D5-A374-302967D50E35Q27005960-ABEB303A-E9FD-444E-8E3C-7E363445BB46Q33382757-4F8BA767-AED8-40D7-8210-76FAA19E1268Q33383571-1C879406-B96D-436F-8A3E-E0F539F6085AQ33401218-382AF285-7897-4A8C-BDCC-5325C23AB13AQ33702412-A27308EC-4A59-4958-BA83-56D98A06447EQ33721126-1AEF5875-B534-4D6A-9444-172332262932Q33843955-B1558BB0-543B-4BA5-8227-B73AC6859231Q34021009-6BCB03FA-7782-4755-8A16-8DE611841FE5Q34150263-788C172A-CBFE-46FC-8B7A-9A278B1F5F43Q34154708-D9848C60-7E58-4170-948A-13640022A2ECQ34267853-C6F44C00-DABF-4334-9814-28A36FEAFAE7Q34298181-2EFC6F43-62FD-4F09-AAD6-A86B053DB5AAQ34500856-80A178A9-E0FB-45B0-88C9-60176D828669Q34679387-00448304-7A55-43D6-BA76-2B0B56FB6652Q34686726-DC4579DC-C6E4-417F-8B7A-03A4E42AB110Q34754350-F548C386-F4C6-48DD-B802-761028A4F07EQ34982576-1D8E06DB-9421-4924-8188-2E3D8842C072Q35000135-6F82E75A-D452-4F3E-816D-34F96FF41E48Q35009273-26729CB6-8EB1-49DB-B3D7-EC293EFFD6FEQ35057041-62DD0A23-8F60-4C96-9763-B16634BAC89DQ35278018-26293BE5-0AD4-4C69-8B58-32BFDBC6404AQ35296104-21D7A745-ADAB-4EB3-B54D-9BF3888B6C44Q35546759-68AD3CAA-E214-4725-91A4-477570295853Q35584427-A275F1EC-404E-4A60-8A82-173340A58465Q35605949-7D94BB94-11C7-4302-A8F2-7AE85124C6C2Q35740894-F292F432-01BD-4086-82CE-DBF98939901AQ35761309-34414B90-B417-4804-930F-94834CCBC493Q35990683-2A29A97A-4753-49EC-BD86-DA969C5EC790Q36075766-5E0946D3-1CC0-4F15-9559-CA061DFC83ECQ36094977-786E7958-9515-441A-8785-5C6299A90E0AQ36161733-BA9E175D-0522-4E7D-994C-9F065AD74340Q36731404-C1C7896C-9253-4978-B830-15CFECBF2698Q36776439-2E687097-BE70-47BA-95AA-1678676C805BQ36806921-DA3468B9-8F51-4861-8B9A-9980A123E3C3Q36915178-04E4118E-3087-440B-9E4F-A068290DC383Q37270982-F819F0A9-716C-471E-AE4C-DC4AFD8B0325Q37693943-91F72CA0-6CEE-48D9-BB72-F0295A638524Q37840260-890F0EA1-C379-4897-B067-7D50643E60EF
P2860
Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Results of a phase 1-2 study o ...... nd refractory acute leukemias.
@en
Results of a phase 1-2 study of clofarabine in combination with cytarabine
@nl
type
label
Results of a phase 1-2 study o ...... nd refractory acute leukemias.
@en
Results of a phase 1-2 study of clofarabine in combination with cytarabine
@nl
prefLabel
Results of a phase 1-2 study o ...... nd refractory acute leukemias.
@en
Results of a phase 1-2 study of clofarabine in combination with cytarabine
@nl
P2093
P50
P1433
P1476
Results of a phase 1-2 study o ...... nd refractory acute leukemias.
@en
P2093
Elihu Estey
Francis J Giles
Miloslav Beran
Monica Kwari
Peter Bonate
Varsha Gandhi
P304
P356
10.1182/BLOOD-2004-05-1933
P407
P50
P577
2004-10-14T00:00:00Z